SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
Following is the text of additional presentation materials delivered to
ICN Pharmaceuticals, Inc. stockholders on or about May 17, 2002:
Information an ICN Stockholder may want to Consider
PROVIDENCE/DENTON* TRACK RECORD**
[Bar Graph Omitted]
o 5 of 9 companies bankrupt
Stock Price
o Approximate date of Providence/
Denton's Initial Involvement
o Current: 5/14/02
Standard Brands
4/29/91 $72.50
5/14/02 $0.00(1)
California Microwave
11/8/96 $14.50
5/14/02 $0.00(1)
Chic (Durango)
1/13/98 $7.06
5/14/02 $0.00(1)
Iwerks
3/17/98 $10.94
5/14/02 $0.63(2)
Ogden (Covanta)
4/27/98 $29.50
5/14/02 $0.00(1)
Great Lakes
2/15/99 $35.75
5/14/02 $26.70
AP Pharma
4/22/99 $5.38
5/14/02 $2.27
Baldwin Piano
9/3/99 $8.13
5/14/02 $0.00(1)
USG
5/10/00 $41.81
5/14/02 $6.95
Notes:
(1) Company entered into bankruptcy
(2) Acquired 1/10/02
Source: FactSet and Bloomberg
Don't put ICN in the red column
VOTE THE GOLD CARD FOR ICN
* Providence Capital, Inc., of which Herbert A. Denton is President, is
acting as financial adviser to Franklin Mutual Advisers, LLC and Iridian
Asset Management LLC in connection with their nomination of three directors
for election at ICN's 2002 Annual Meeting of Stockholders. Providence was
also a member of the ICN Committee to Maximize Shareholder Value, which
nominated three directors who were elected at ICN's 2001 Annual Meeting of
Stockholders.
** Includes nine companies in which Providence made an investment or
Providence or stockholders on whose behalf it was acting sought to
influence management out of 28 such companies identified by ICN, based on
publicly available information. These nine companies were selected because
these companies experienced the worst performance among the 28 companies
following Providence's investment or other involvement. This graph should
not be read to imply that Providence's investment or other involvement was
the cause of the decline in stock price.